AMENDMENTS TO THE CLAIMS

The below listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Currently amended) A therapeutic composition for the treatment or prophylaxis of rheumatoid arthritis, wherein the composition comprises a purified β-glucuronidase enzyme and purified collagen, the β-glucuronidase enzyme and the collagen being present in the composition at a dose which provides a beneficial effect to an individual in need of treatment or prophylaxis.

2-3. (Cancelled)

4. (Currently amended) The composition of claim 1 [[3]], wherein the β-glucuronidase enzyme is β-D-glucuronoside glucuronosohydrolase (Registry number EC 3.2.1.31).

5. (Original) The composition of claim 1, wherein the enzyme is present at a concentration of between 200 and 10,000 Fishman units/ml.

6. (Original) The composition of claim 1, wherein the enzyme is present at a concentration of between 0.5 and 2.5 mg/ml.

7. (Cancelled)

8. (Cancelled)

9. (Currently amended) The composition of claim 7, further comprising ~~wherein the stabiliser and/or activator is selected from the group consisting of~~ protamine sulphate ~~and~~ or 1,10 diamino decane.

10. (Currently amended) The composition of claim 7, wherein the protamine sulphate or 1,10 diamino decane ~~stabiliser and/or activator~~ is present at a concentration of 3-9 ~~up to 20 mg~~/[[l]]L.

11. (Currently amended) A therapeutic composition for the treatment or prophylaxis of rheumatoid arthritis, the composition comprising a purified β-glucuronidase enzyme, purified collagen, and 1,3 cyclohexane diol and/or protamine sulphate or 1,10 diamino decane ~~a stabiliser and/or activator~~, the β-glucuronidase enzyme and the collagen being present in the composition at a dose which provides a beneficial effect to an individual in need of treatment or prophylaxis~~, wherein the composition further comprises hydroxyl moieties~~.

12. (Cancelled) ~~The composition of claim 11, wherein the hydroxyl moieties are provided by sugars or diols.~~

13. (Cancelled) ~~The composition of claim 11, wherein the hydroxyl moieties are provided by 1,3 cyclohexane diol.~~

14. (Currently amended) The composition of claim 11, wherein the protamine sulphate or 1,10 diamino decane ~~hydroxyl moieties~~ are present at a concentration of ~~up to 20~~ 3-9 µg/[[l]]L and the cyclohexane diol is present at a concentration of 1 µg/ml.

15. (Previously presented) The composition of claim 1, wherein the composition is buffered to an acid or neutral pH.

16. (Original) The composition of claim 15, wherein the composition is buffered to a pH of between 5 and 6.

17. (Canceled)

18. (Currently amended) The composition of claim 1[[17]], wherein the collagen is present at a concentration of between 10 and 1 x 10^{15} molecules/ml.

19. (Previously presented) The composition of claim 1, wherein the composition further comprises a glycosaminoglycan.

20. (Currently amended) The composition according to claim 19, wherein the glycosaminoglycan is selected from the group consisting of hyaluronate ~~(D glucuronic acid N acetyl D glucosamine)~~, chondroitin sulphate ~~(D glucuronic acid N acetyl D galactosamine 4 or 6 sulphate)~~, dermatan sulphate ~~(D glucuronic acid or L iduronic acid N acetyl D galactosamine)~~, keratan sulphate ~~(D galactose N acetyl D glucosamine sulphate)~~, and heparan sulphate ~~(D glucuronic acid or L iduronic acid N acetyl D glucosamine)~~.

21. (Original) The composition of claim 19, wherein the glycosaminoglycan is chondroitin -6- sulphate.

22. (Original) The composition of claim 19, wherein the glycosaminoglycan is present at a concentration of between 0.1 and 1.0 mg/ml.

23. (Previously presented) The composition of claim 1, wherein the composition is in a formulation suitable for transdermal infusion or intradermal injection.

24. (Previously presented) A kit for preparing the composition of claim 1, wherein the kit comprises a β-glucuronidase enzyme solution and a collagen solution, and the two solutions are introduced to one another and allowed to admix prior to administration to an individual in need of treatment of arthritis.

25-28. (Cancelled)

29. (Previously presented) A composition comprising 1,000 to 5,000 Fishman units/ml β-glucuronidase, 6 µg/ml protamine sulphate, 1 µg/ml 1,3 cyclohexane diol, and 0.5 mg/ml chondroitin sulphate, buffered to pH 5.9 and a concentration of collagen selected from the group consisting of 2.5×10^{12}, 2.5×10^{10} and 2.5×10^{4} molecules/ml for use in the treatment of rheumatoid arthritis.

30. (Withdrawn) A method of using the composition of claim 1 or 11, for the treatment of arthritis.

31. (Withdrawn/Currently amended) A method of using the composition of claim 29, for the treatment of rheumatoid arthritis.

32. (Withdrawn) A therapeutic composition for the treatment or prophylaxis of multiple sclerosis, wherein the composition comprises a β-glucuronidase enzyme and myelin, the β-glucuronidase enzyme and the myelin being present in the composition at a dose which provides a beneficial effect to an individual in need of treatment.

`33. (New) The composition of claim 20, wherein hyaluronate comprises D glucuronic acid N acetyl D glucosamine; chondroitin sulphate comprises D glucuronic acid N acetyl D galactosamine 4 or 6 sulphate, dermatan sulphate comprises D glucuronic acid or L iduronic acid N acetyl D galactosamine, keratan sulphate comprises D galactose N acetyl D glucosamine sulphate, and/or heparan sulphate comprises D glucuronic acid or L iduronic acid N acetyl D glucosamine.